Hidenori Ibata

807 total citations
29 papers, 574 citations indexed

About

Hidenori Ibata is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Hidenori Ibata has authored 29 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 4 papers in Surgery. Recurrent topics in Hidenori Ibata's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (6 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Hidenori Ibata is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (6 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Hidenori Ibata collaborates with scholars based in Japan, United States and Greece. Hidenori Ibata's co-authors include Esteban C. Gabazza, Osamu Taguchi, Shiro Suzuki, Hideo Saka, Akihito Kubo, Yoshio Okano, Masahiko Ando, Atsuhisa Tamura, Tomoya Kawaguchi and Kazuhiro Sakamoto and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and CHEST Journal.

In The Last Decade

Hidenori Ibata

27 papers receiving 562 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hidenori Ibata Japan 14 391 275 61 61 56 29 574
Kelley A. Barney United States 4 122 0.3× 214 0.8× 104 1.7× 88 1.4× 94 1.7× 5 479
Andreas duBois Germany 9 105 0.3× 291 1.1× 110 1.8× 59 1.0× 82 1.5× 15 713
M. Veslemes Greece 16 563 1.4× 788 2.9× 350 5.7× 25 0.4× 92 1.6× 39 1.0k
Martin Friedrich Germany 12 127 0.3× 244 0.9× 219 3.6× 47 0.8× 142 2.5× 17 758
Isabelle Genvresse Germany 12 105 0.3× 157 0.6× 107 1.8× 13 0.2× 23 0.4× 27 472
Sven Borchmann Germany 15 110 0.3× 298 1.1× 83 1.4× 20 0.3× 79 1.4× 46 612
Minna Voigtlaender Germany 9 69 0.2× 108 0.4× 120 2.0× 36 0.6× 77 1.4× 22 341
Hideki Ueno Japan 14 140 0.4× 389 1.4× 192 3.1× 20 0.3× 168 3.0× 44 706
Erjiang Tang China 10 117 0.3× 177 0.6× 58 1.0× 13 0.2× 75 1.3× 22 368
Laura Attademo Italy 13 60 0.2× 225 0.8× 172 2.8× 111 1.8× 100 1.8× 21 560

Countries citing papers authored by Hidenori Ibata

Since Specialization
Citations

This map shows the geographic impact of Hidenori Ibata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hidenori Ibata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hidenori Ibata more than expected).

Fields of papers citing papers by Hidenori Ibata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hidenori Ibata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hidenori Ibata. The network helps show where Hidenori Ibata may publish in the future.

Co-authorship network of co-authors of Hidenori Ibata

This figure shows the co-authorship network connecting the top 25 collaborators of Hidenori Ibata. A scholar is included among the top collaborators of Hidenori Ibata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hidenori Ibata. Hidenori Ibata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nishimura, T., Hajime Fujimoto, Taro Yasuma, et al.. (2024). Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach. Diagnostics. 14(19). 2159–2159.
2.
Nishimura, T., Hajime Fujimoto, Masahiro Naito, et al.. (2023). Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma. Thoracic Cancer. 14(7). 709–713. 2 indexed citations
3.
Asai, Yuki, et al.. (2023). Impact of antimicrobial stewardship program-driven educational intervention for vancomycin loading dose on mortality. Journal of Infection and Chemotherapy. 29(11). 1023–1032.
4.
Nishimura, T., Hajime Fujimoto, Masahiro Naito, et al.. (2022). Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?. Cancers. 14(12). 2970–2970. 3 indexed citations
5.
6.
Nishimura, T., Masahiro Naito, Taro Yasuma, et al.. (2021). Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report. World Journal of Clinical Cases. 9(23). 6922–6928. 16 indexed citations
7.
Nishimura, T., et al.. (2020). A Case of Nonbacterial Thrombotic Endocarditis Following Immune Checkpoint Inhibitor Treatment for Lung Adenocarcinoma. Haigan. 60(3). 174–180. 1 indexed citations
8.
9.
Kawaguchi, Tomoya, Masahiko Ando, Kazuhiro Asami, et al.. (2014). Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). Journal of Clinical Oncology. 32(18). 1902–1908. 197 indexed citations
10.
11.
12.
Fujiwara, Atsushi, Hiroyasu Kobayashi, Masahiro Masuya, et al.. (2012). Correlation between circulating fibrocytes, and activity and progression of interstitial lung diseases. Respirology. 17(4). 693–698. 45 indexed citations
13.
Ibata, Hidenori, et al.. (2009). The Usefulness of Inspiratory Flow Rate during Inhalation Corticosteroid Therapy in Asthma. Respiration. 78(4). 387–392. 5 indexed citations
14.
Shimada, Izumi, et al.. (2007). Cooling Sodium Alginate Has Stronger Analgesic Effect with Respect to Adverse Reaction-induced Pain in Radiotherapy. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 33(11). 920–924. 1 indexed citations
15.
Taguchi, Osamu, Esteban C. Gabazza, Masami Yoshida, et al.. (1997). Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise. European Respiratory Journal. 10(9). 2055–2060. 42 indexed citations
16.
Gabazza, Esteban C., et al.. (1994). Alteration of coagulation and fibrinolysis systems after multidrug anticancer therapy for lung cancer. European Journal of Cancer. 30(9). 1276–1281. 16 indexed citations
17.
Gabazza, Esteban C., et al.. (1993). Correlation between increased granulocyte elastase release and activation of blood coagulation in patients with lung cancer. Cancer. 72(7). 2134–2140. 17 indexed citations
18.
Gabazza, Esteban C., et al.. (1993). Clinical Characteristics of Pulmonary Tuberculosis in the Compromised Host. Kansenshogaku zasshi. 67(6). 556–560. 1 indexed citations
19.
Gabazza, Esteban C., et al.. (1992). Coagulation-fibrinolysis system and markers of collagen metabolism in lung cancer. Cancer. 70(11). 2631–2636. 27 indexed citations
20.
Ibata, Hidenori, et al.. (1989). Clinical effects of CAMOSTAT in chronic pancreatitis. Biomedical Research-tokyo. 10. 145–150. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kelley A. Barney Breakdown of academic impact, for papers by Andreas duBois Breakdown of academic impact, for papers by M. Veslemes Breakdown of academic impact, for papers by Martin Friedrich Breakdown of academic impact, for papers by Isabelle Genvresse Breakdown of academic impact, for papers by Sven Borchmann Breakdown of academic impact, for papers by Minna Voigtlaender Breakdown of academic impact, for papers by Hideki Ueno Breakdown of academic impact, for papers by Erjiang Tang Breakdown of academic impact, for papers by Laura Attademo
Rankless by CCL
2026